Regulation of LDLR, Bcl-2 and FASN Expressions by Oxidized Low Density Lipoprotein in Estrogen Receptor Positive Breast Cancer Cells

Q4 Pharmacology, Toxicology and Pharmaceutics

Current Pharmacogenomics and Personalized Medicine Pub Date : 2018-05-31 DOI:10.2174/1875692116666180416150402

Auni Hamid, Siti Aminah Ahmed, S. Hamid

引用次数: 0

查看原文本刊更多论文

氧化低密度脂蛋白对雌激素受体阳性乳腺癌细胞中LDLR、Bcl-2和FASN表达的调控

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Pharmacogenomics and Personalized Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.